| Cover Page - shares | 9 Months Ended | |
| Sep. 30, 2024 | Nov. 12, 2024 |
| Document Information [Line Items] | | |
| Document Type | 10-Q/A | |
| Amendment Flag | true | |
| Document Period End Date | Sep. 30, 2024 | |
| Document Fiscal Year Focus | 2024 | |
| Document Fiscal Period Focus | Q3 | |
| Trading Symbol | SCPH | |
| Entity Registrant Name | SCPHARMACEUTICALS INC. | |
| Entity Central Index Key | 0001604950 | |
| Current Fiscal Year End Date | --12-31 | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Current Reporting Status | Yes | |
| Entity Small Business | true | |
| Entity Emerging Growth Company | false | |
| Entity Shell Company | false | |
| Entity Interactive Data Current | Yes | |
| Title of 12(b) Security | Common stock, par value $0.0001 per share | |
| Security Exchange Name | NASDAQ | |
| Entity File Number | 001-38293 | |
| Entity Incorporation, State or Country Code | DE | |
| Entity Tax Identification Number | 46-5184075 | |
| Entity Address, Address Line One | 25 Mall Road | |
| Entity Address, Address Line Two | Suite 203 | |
| Entity Address, City or Town | Burlington | |
| Entity Address, State or Province | MA | |
| Entity Address, Postal Zip Code | 01803 | |
| City Area Code | 617 | |
| Local Phone Number | 517-0730 | |
| Document Quarterly Report | true | |
| Document Transition Report | false | |
| Entity Common Stock, Shares Outstanding | | 50,040,134 |
| Amendment Description | EXPLANATORY NOTE scPharmaceuticals Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (this “Amendment”) to its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, which was originally filed with the Securities and Exchange Commission (the “SEC”) on November 13, 2024 (the “Original Filing”) to amend Part II “Item 5. Other Information” by adding disclosure regarding “Rule 10b5-1 trading arrangements” as defined in Item 408(a) of Regulation S-K that were entered into during the quarter ended September 30, 2024 by each of (i) John H. Tucker, the Company’s President and Chief Executive Officer and (ii) Rachael Nokes, the Company’s Chief Financial Officer. In addition, as required by Rule 12b-15 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), new certifications by the Company’s principal executive officer and principal financial officer are filed herewith as exhibits to this Amendment, under Part II “Item 6. Exhibits” hereof, pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. The Company is also not including new certifications under Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) (Section 906 of the Sarbanes-Oxley Act of 2002, as amended), as no financial statements are being filed with this Amendment. Other than as expressly set forth herein, this Amendment does not, and does not purport to, amend, update or restate the information in Original Filing or reflect any events that have occurred after the Original Filing was made. Information not affected by this Amendment remains unchanged and reflects the disclosures made at the time as of which the Original Filing was made. No changes have been made to the financial statements of the Company as contained in the Original Filing. Accordingly, this Amendment should be read together with the Original Filing and the Company’s other filings with the SEC. | |
